Use of sodium bicarbonate to promote weight gain, maintain body temperature, normalize renal functions and minimize mortality in rodents receiving the chemotherapeutic agent cisplatin

Neuroscience Letters

Volumn 544, Issue , 2013, Pages 41-46

  Guindon, Josée ^a,b   Hohmann, Andrea G ^a,b  

^a INDIANA UNIVERSITY   (United States)

^b University of Georgia ^*  (United States)

Author keywords

ANOVA; BL; Chemotherapy induced peripheral neuropathy; Creatinine; Hypothermia; I.p.; Inj; Kidney function; NaCl; NaHCO3; NaHCO3 (sodium bicarbonate); S.c.; Weight loss

Indexed keywords

BICARBONATE; CISPLATIN; CREATININE; KETONE;

ALLODYNIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY TEMPERATURE; CONTROLLED STUDY; KIDNEY FUNCTION; KIDNEY MASS; MALE; MORTALITY; NEPHROTOXICITY; NONHUMAN; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RAT; WEIGHT GAIN; WEIGHT REDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; BODY TEMPERATURE REGULATION; CISPLATIN; DRUG INTERACTIONS; KIDNEY; MALE; PERIPHERAL NERVOUS SYSTEM DISEASES; RATS; RATS, SPRAGUE-DAWLEY; RENAL INSUFFICIENCY; SODIUM BICARBONATE; WEIGHT GAIN;

EID: 84878381134     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2013.03.033     Document Type: Article

References (31)

1. Alberts D.S., Noel J.K. Cisplatin-associated neurotoxicity: can it be prevented. Anticancer Drugs 1995, 6:369-383.
2. Antunes L.M., Darin J.D., Bianchi M.D. Protective effects of vitamin c against cisplatin-induced nephrotoxicity and lipid peroxidation in adult rats: a dose-dependent study. Pharmacol. Res. 2000, 41:405-411.
3. Askew E.W., Dohm G.L., Huston R.L. Fatty acid and ketone body metabolism in the rat: response to diet and exercise. J. Nutr. 1975, 105:1422-1432.
4. Authier N., Balayssac D., Marchand F., Ling B., Zangarelli A., Descoeur J., Coudore F., Bourinet E., Eschalier A. Animal models of chemotherapy-evoked painful peripheral neuropathies. Neurotherapeutics 2009, 6:620-629.
5. Authier N., Fialip J., Eschalier A., Coudoré F. Assessment of allodynia and hyperalgesia after cisplatin administration to rats. Neurosci. Lett. 2000, 291:73-76.
6. Authier N., Gillet J.P., Fialip J., Eschalier A., Coudore F. An animal model of nociceptive peripheral neuropathy following repeated cisplatin injections. Exp. Neurol. 2003, 182:12-20.
7. Bacci G., Ferrari S., Longhi A., Forni C., Loro L., Beghelli C., Tremosini M., Versari M. Delayed methotrexate clearance in osteosarcoma patients treated with multiagent regimens of neoadjuvant chemotherapy. Oncol. Rep. 2003, 10:851-857.
8. Boyiadzis M.M., Lebowitz P.F., Frame J.N., Fojo T. Hematology-Oncology Therapy 2007, McGraw Hill, Medical Publishing Division, New York.
9. Do Amaral C.L., Francescato H.D., Coimbra T.M., Costa R.S., Darin J.D., Antunes L.M., Bianchi M.de L. Resveratrol attenuates cisplatin-induced nephrotoxicity in rats. Arch. Toxicol. 2008, 82:363-370.
10. Elwell M.R., Sammons M.L., Liu C.T., Beisel W.R. Changes in blood pH in rats after infection with Streptococcus pneumoniae. Infect. Immun. 1975, 11:724-726.
11. Guindon J., Lai Y., Takacs S.M., Bradshaw H.B., Hohmann A.G. Alterations in endocannabinoid tone following chemotherapy-induced peripheral neuropathy: effects of endocannabinoid deactivation inhibitors targeting fatty-acid amide hydrolase and monoacylglycerol lipase in comparison to reference analgesics following cisplatin treatment. Pharmacol. Res. 2013, 67:94-109.
12. Haylor J., Lote C.J. Urine pH and the relationship between urine flow and urinary prostaglandin E excretion in the rat. J. Endocrinol. 1986, 108:247-253.
13. Hillyer E.V., Quesenberry K.E. Ferrets, Rabbits and Rodents; Clinical Medicine and Surgery 1996, Elsevier Health Science, New York. 1st ed.
14. Işeri S., Ercan F., Gedik N., Yüksel M., Alican I. Simvastatin attenuates cisplatin-induced kidney and liver damage in rats. Toxicology 2007, 230:256-264.
15. Keppler A., Gretz N., Schimdt R., Kloetzer H.M., Groene H.J., Lelongt B., Meyer M., Sadick M., Pill J. Plasma creatinine determination in mice and rats: an enzymatic method compares favorably with a high-performance liquid chromatography assay. Kidney Int. 2007, 71:74-78.
16. Kishore B.K., Krane C.M., Di Iulio D., Menon A.G., Cacini W. Expression of renal aquaporins 1, 2, and 3 in a rat model of cisplatin-induced polyuria. Kidney Int. 2000, 58:701-711.
17. Koch D.D., Feldbruegge D.H. Optimized kinetic method for automated determination of beta- hydroxybutyrate. Clin. Chem. 1987, 33:1761-1766.
18. Liu M., Chien C., Burne-Taney M., Molls R.R., Racusen L.C., Colvin R.B., Rabb H. A pathophysiologic role for T lymphocytes in murine acute cisplatin nephrotoxicity. J. Am. Soc. Nephrol. 2006, 17:765-774.
19. McCarty M.F., Whitaker J. Manipulating tumor acidification as a cancer treatment strategy. Altern. Med. Rev. 2010, 15:264-272.
20. Perry M.C. Companion Handbook to the Chemotherapy Sourcebook 1999, Williams & Wilkins, Baltimore.
21. Mir O., Ropert S., Babinet A., Alexandre J., Larousserie F., Durand J.P., Enkaoua E., Anract P., Goldwasser F. Hyper-alkalinization without hyper-hydration for the prevention of high-dose methotrexate acute nephrotoxicity in patients with osteosarcoma. Cancer Chemother. Pharmacol 2010, 66:1059-1063.
22. Sánchez-González P.D., López-Hernández F.J., López-Novoa J.M., Morales A.I. An integrative view of the pathophysiological events leading to cisplatin nephrotoxicity. Crit. Rev. Toxicol. 2011, 41:803-821.
23. Schroeder H.A. Serum cholesterol and glucose levels in rats fed refined and less refined sugars and chromium. J. Nutr. 1969, 97:237-242.
24. Sean Eardley K., Cockwell P. Macrophages and progressive tubulointerstitial disease. Kidney Int. 2005, 68:437-455.
25. Silva A.S., Yunes J.A., Gillies R.J., Gatenby R.A. The potential role of systemic buffers in reducing intratumoral extracellular pH and acid-mediated invasion. Cancer Res. 2009, 69:2677-2684.
26. Vera G., Chiarlone A., Cabezos P.A., Pascual D., Martín M.I., Abalo R. WIN 55,212-2 prevents mechanical allodynia but not alterations in feeding behaviour induced by chronic cisplatin in the rat. Life Sci. 2007, 81:468-479.
27. Vera G., Chiarlone A., Martín M.I., Abalo R. Altered feeding behaviour induced by long-term cisplatin in rats. Auton. Neurosci. 2006, 126/127:81-92.
28. Wiffen P.J. Enhanced glucose control for preventing and treating diabetic neuropathy. J. Pain Palliat. Care Pharmacother. 2012, 26:380.
29. Wong P., Lee C., Tannock I.F. Reduction of intracellular pH as a strategy to enhance the pH-dependent cytotoxic effects of melphalan for human breast cancer cells. Clin. Cancer Res. 2005, 11:3553-3557.
30. Yao X., Panichpisal K., Kurtzman N., Nugent K. Cisplatin nephrotoxicity: a review. Am. J. Med. Sci. 2007, 334:115-124.
31. Zimmermann M. Ethical guidelines for investigations of experimental pain in conscious animals. Pain 1983, 16:109-110.